Free Trial
NASDAQ:ATXS

Astria Therapeutics (ATXS) Stock Price, News & Analysis

Astria Therapeutics logo
$7.47 -0.22 (-2.86%)
Closing price 04:00 PM Eastern
Extended Trading
$7.53 +0.06 (+0.75%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Astria Therapeutics Stock (NASDAQ:ATXS)

Advanced

Key Stats

Today's Range
$7.36
$7.78
50-Day Range
$6.18
$7.84
52-Week Range
$3.56
$12.52
Volume
365,841 shs
Average Volume
437,662 shs
Market Capitalization
$421.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.50
Consensus Rating
Moderate Buy

Company Overview

Astria Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
53rd Percentile Overall Score

ATXS MarketRank™: 

Astria Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 529th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Astria Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 7 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Astria Therapeutics has a consensus price target of $29.50, representing about 294.9% upside from its current price of $7.47.

  • Amount of Analyst Coverage

    Astria Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Astria Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Astria Therapeutics are expected to decrease in the coming year, from ($1.65) to ($1.78) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Astria Therapeutics is -3.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Astria Therapeutics is -3.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Astria Therapeutics has a P/B Ratio of 1.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Astria Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    6.49% of the float of Astria Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Astria Therapeutics has a short interest ratio ("days to cover") of 9.2.
  • Change versus previous month

    Short interest in Astria Therapeutics has recently increased by 5.38%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Astria Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Astria Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.49% of the float of Astria Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Astria Therapeutics has a short interest ratio ("days to cover") of 9.2.
  • Change versus previous month

    Short interest in Astria Therapeutics has recently increased by 5.38%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Astria Therapeutics has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Astria Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    5 people have searched for ATXS on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Astria Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Astria Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.50% of the stock of Astria Therapeutics is held by insiders.

  • Percentage Held by Institutions

    98.98% of the stock of Astria Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Astria Therapeutics' insider trading history.
Receive ATXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Astria Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ATXS Stock News Headlines

An $8 trillion-dollar discovery 17,000 ft underwater
A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.tc pixel
See More Headlines

ATXS Stock Analysis - Frequently Asked Questions

Astria Therapeutics' stock was trading at $8.94 at the beginning of the year. Since then, ATXS stock has decreased by 16.4% and is now trading at $7.47.

Astria Therapeutics, Inc. (NASDAQ:ATXS) issued its quarterly earnings data on Tuesday, August, 12th. The biotechnology company reported ($0.57) earnings per share for the quarter, topping analysts' consensus estimates of ($0.61) by $0.04.

Astria Therapeutics shares reverse split on Friday, August 20th 2021.The 1-6 reverse split was announced on Friday, August 20th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

Shares of ATXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Astria Therapeutics investors own include CRISPR Therapeutics (CRSP), Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
8/12/2025
Today
10/07/2025
Next Earnings (Estimated)
11/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ATXS
CIK
1454789
Employees
30
Year Founded
2008

Price Target and Rating

High Price Target
$49.00
Low Price Target
$20.00
Potential Upside/Downside
+294.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$94.26 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-56.39%
Return on Assets
-36.08%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
14.89
Quick Ratio
14.89

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.97 per share
Price / Book
1.88

Miscellaneous

Outstanding Shares
56,435,000
Free Float
53,895,000
Market Cap
$421.57 million
Optionable
Optionable
Beta
0.43

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:ATXS) was last updated on 10/7/2025 by MarketBeat.com Staff
From Our Partners